ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1351

The Impact of Skin Involvement and Depression on Patient Acceptable Symptom State in Patients with Psoriatic Arthritis and Psoriasis: Results from a Multinational Survey

Alexis Ogdie-Beatty1, Joseph Merola2, Pascal Richette3, Sven Richter4, Shauna Jardon5, Lihua Tang4 and William Tillett6, 1University of Pennsylvania, Philadelphia, PA, 2Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, 3Lariboisiere Hospital, Paris, France, 4Amgen Inc., Thousand Oaks, CA, 5Amgen Inc., Gilbert, AZ, 6Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

Meeting: ACR Convergence 2021

Keywords: Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 8, 2021

Title: Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Depression, a common comorbidity in patients with psoriasis (PsO) and PsA, has been shown to be independently associated with Psoriatic Arthritis Impact of Disease (PsAID-12) scores. We investigated how much active PsO and a positive 2-item Patient Health Questionnaire (PHQ-2) depression screen impacted PsAID-12 scores in patients with PsA in the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey.

Methods: UPLIFT was a multinational Web-based survey conducted in 2020 in adults who reported ever being diagnosed by a healthcare provider (HCP) with PsA and/or PsO. For patients with PsA, we report PsAID-12 total and domain scores and Patient Acceptable Symptom State (PASS) achievement (PsAID-12 ≤4) according to the presence of active PsO and depression status. A PHQ-2 score ≥3 indicates a positive screen for depression.

Results: Of the 3,806 patient survey respondents, 1,256 reported HCP-diagnosed PsA, of which 1,064 had HCP-diagnosed PsA + active PsO and 192 had PsA only. In patients with PsA + PsO, enthesitis (44.5%), dactylitis (47.0%), and polyarthritis (59.8%) were more prevalent than in patients with PsA without active PsO (37.5%, 37.5%, and 36.5%, respectively). More patients with PsA + PsO vs PsA only had a history of patient-reported HCP-diagnosed comorbidities, including depression (42.7% vs 26.6%), cancer (30.7% vs 21.4%), heart disease (23.1% vs 13.5%), hypertension (44.0% vs 33.3%), liver disease (21.0% vs 12.5%), and inflammatory bowel disease (25.5% vs 14.1%). Despite differences in comorbidity burden, mean total PsAID-12 scores (Figure 1) and rates of PASS achievement (25.0% vs 26.9%) were similar in patients with PsA only and PsA + PsO. Mean individual PsAID-12 domain scores were generally similar between groups; however, impact of “skin problems” and “embarrassment and/or shame” was more pronounced for the PsA + PsO group (Figure 1). A total of 67% of PsA only and 66% PsA + PsO patients had a PHQ-2 ≥3. Patients with PHQ-2 ≥3 had higher PsAID-12 scores, indicating worse health status, regardless of whether they had active PsO. Fewer patients with PHQ-2 ≥3 achieved PASS (PsA: 10.9%, PsA + PsO: 10.7%) compared with those who screened negative for depression (PsA: 53.1%, PsA + PsO 58.8%). Similarly, higher PsAID-12 domain scores were reported in patients with PsA with PHQ-2 ≥3 vs those with PHQ-2 ≤2 (Figure 2) and to a greater extent in those with PsA + PsO (Figure 3). The greatest differences between groups were observed in domains of “work and/or leisure activities,” “coping,” “anxiety, fear, and uncertainty,” “embarrassment and/or shame,” and “social participation.”

Conclusion: For patients with PsA in UPLIFT, active PsO was associated with generally more active disease and a higher prevalence of comorbidities, including depression. Having a positive PHQ-2 screen for depression was associated with overall disease impact as measured by PsAID.


Disclosures: A. Ogdie-Beatty, AbbVie, 2, Amgen, 2, 5, BMS, 2, Celgene, 2, CorEvitas (formerly Corrona), 2, Janssen, 2, Eli Lilly, 2, Novartis, 2, Pfizer, 2, UCB, 2, National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, 5, Rheumatology Research Foundation, 5, National Psoriasis Foundation, 5, Pfizer (to University of Pennsylvania), 5, AbbVie (to University of Pennsylvania), 5, Novartis (to University of Pennsylvania), 5, Gilead, 2; J. Merola, AbbVie, 2, Arena, 2, Biogen, 2, Dermavant Sciences, 2, Eli Lilly, 2, Janssen, 2, Novartis, 2, Pfizer Inc, 2, Sun Pharma, 2, UCB Pharma, 2, Avotres Inc, 2, Celgene, 2, EMD Serono, 2, Regeneron, 2, Sanofi, 2, Leo Pharma, 2, Merck, 2, Bristol-Myers Squibb, 2; P. Richette, AbbVie, 1, 6, Amgen, 1, 6, Celgene, 1, 6, Janssen, 1, 6, Eli Lilly, 1, 6, MSD, 1, 6, Novartis, 1, 6, Pfizer, 1, 6, UCB, 1, 6; S. Richter, Amgen Inc., 3, 11; S. Jardon, Amgen Inc., 3, 11; L. Tang, Amgen Inc., 3, 11; W. Tillett, AbbVie, 1, 2, 6, Amgen, 1, 2, 6, Celgene, 1, 2, 6, Eli Lilly, 1, 2, 6, Janssen, 1, 2, 6, Novartis, 1, 2, 6, MSD, 1, 2, 6, Pfizer, 1, 2, 6, UCB, 1, 2, 6, Merck Sharp & Dohme, 2.

To cite this abstract in AMA style:

Ogdie-Beatty A, Merola J, Richette P, Richter S, Jardon S, Tang L, Tillett W. The Impact of Skin Involvement and Depression on Patient Acceptable Symptom State in Patients with Psoriatic Arthritis and Psoriasis: Results from a Multinational Survey [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/the-impact-of-skin-involvement-and-depression-on-patient-acceptable-symptom-state-in-patients-with-psoriatic-arthritis-and-psoriasis-results-from-a-multinational-survey/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-skin-involvement-and-depression-on-patient-acceptable-symptom-state-in-patients-with-psoriatic-arthritis-and-psoriasis-results-from-a-multinational-survey/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology